Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug, FS120, to see if it is safe and effective in treating people with advanced cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant, breastfeeding, and if able to bear children, I use effective birth control.I have another cancer that is growing or was treated in the last 3 years.My cancer is advanced, cannot be surgically removed, and is of a specific type.I haven't had cancer treatment in the last 28 days or 5 half-lives of the drug, whichever is shorter.I am 18 years old or older.I have not had treatments targeting OX40, CD137, CD40, GITR, or CD27.I am HIV-positive with a history of Kaposi sarcoma or Castleman Disease.I have had severe side effects from previous immune therapy that haven't improved.I agree to have a biopsy before and during treatment.My cancer is advanced, cannot be surgically removed, and pembrolizumab is approved for my condition.I have not had radiotherapy in the last 2 weeks.I have HIV but am in good health with a low risk of developing AIDS.You have a strong allergic reaction (Grade 3 or higher) to pembrolizumab or any of its ingredients.I have not received a live vaccine in the last 30 days.You must be using a very effective form of birth control.I am fully active or can carry out light work.I do not have uncontrolled brain metastases or tumors.I have been treated with immune-checkpoint inhibitors more than once.
- Group 1: FS120
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum number of individuals permitted to join this clinical trial?
"Absolutely, the published information on clinicaltrials.gov attests to this trial's ongoing recruitment process which commenced in November 2020 and was last updated in August of 2022. There is need for 277 volunteers across three locations."
Are there currently any vacancies for participants of this clinical trial?
"Indeed, the information posted on clinicaltrials.gov confirms that this study is still open for recruitment. It was initially listed on November 18th 2020 and most recently updated in August 8th 2022. The researchers are aiming to acquire 277 patients from 3 different sites."
Has the FS120 medication been given clearance by the FDA?
"FS120 is currently being assessed in a Phase 1 trial, thus the safety rating for this medication was registered as a score of 1 due to scant evidence indicating its efficacy and security."
Share this study with friends
Copy Link
Messenger